Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17661530 | 0.84 | CYP17A1 (0.59) | CYP17A1ALDH1A1LMNASMN1; SMN2GRM1 | |
| SCHEMBL14831365 | 0.82 | CYP17A1 (0.63) | CYP17A1GRM1MAPK14EPHB4RAB9A | |
| SCHEMBL14831378 | 0.81 | CYP17A1 (0.53) | CYP17A1GRM1MAPK14EPHB4RAB9A | |
| SCHEMBL15961992 | 0.79 | CYP17A1 (0.51) | CYP17A1CYP1A2MAPK14EPHB4 | |
| SCHEMBL14831140 | 0.76 | CYP17A1 (0.49) | CYP17A1MAPK14EPHB4 | |
| SCHEMBL28380296 | 0.74 | NR4A2 (0.33) | CYP17A1ALDH1A1LMNASMN1; SMN2CYP1A2 | |
| SCHEMBL14830704 | 0.73 | CYP17A1 (0.77) | CYP17A1CYP1A2MAPK14RPS6KA3 | |
| SCHEMBL14830640 | 0.73 | CYP17A1 (1.00) | CYP17A1ALDH1A1LMNASMN1; SMN2GRM1 | |
| SCHEMBL14830799 | 0.72 | CYP17A1 (0.76) | CYP17A1ALDH1A1LMNASMN1; SMN2GRM1 | |
| SCHEMBL14830510 | 0.71 | EPHB4 (0.32) | CYP17A1ALDH1A1LMNASMN1; SMN2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598436-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| EP-2760870-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-07 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242967-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2015-05-07 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969586-B2 | Substituted bicyclic heteroaryl compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| WO-2013049263-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096847-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP1A2, CYP3A43, CYP4A22 | CYP17A1 35/4885ALDH1A1 523/4885LMNA 3906/4885 |
| US-20140235647-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885ALDH1A1 587/4885LMNA 4039/4885 |
| US-20150126529-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | CYP4A22, CYP1A2, CYP2C18 | CYP17A1 23/4885ALDH1A1 587/4885LMNA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.